We intended to take advantage of its ability to interfere with the function of DRD2, as well as a number of other neuromediator receptors (https://go.drugbank.com/drugs/DB00477), to hamper the pseudo-synaptic, oncogenic interplay between neurons and GBM. This evidence concerns the gene DRD2 and glioblastoma.